Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin Lesions: Histologic, Immunohistologic, and Molecular Biology Findings
- 1 May 2001
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 116 (5), 721-727
- https://doi.org/10.1046/j.0022-202x.2001.01317.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte MaturationJournal of Investigative Dermatology, 2001
- The treatment of psoriasis with IL-10: rationale and review of the first clinical trialsExpert Opinion on Investigational Drugs, 2000
- Treatment of Psoriasis with Interleukin-10Journal of Investigative Dermatology, 1998
- Can Immunomodulatory Molecules Work Topically for Psoriasis?Journal of Investigative Dermatology, 1996
- Co-Localized Overexpression of GRO-α and IL-8 mRNA Is Restricted to the Suprapapillary Layers of Psoriatic LesionsJournal of Investigative Dermatology, 1996
- IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapyClinical and Experimental Immunology, 1995
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.The Journal of Experimental Medicine, 1991
- Overexpression of extracellular matrix receptors (VL-3, 5 and 6) on psoriatic keratinocytesBritish Journal of Dermatology, 1991
- Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytesImmunology Today, 1986